Workflow
Bio-Rad(BIO_B)
icon
Search documents
Bio-Rad(BIO_B) - 2021 Q1 - Quarterly Report
2021-04-29 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange Class B Common Stock, Par Value $0.0001 per share BIOb New York Stock Exchange ☐ TRANSITION REPORT PURSUANT TO SECTION 13 ...
Bio-Rad(BIO_B) - 2020 Q4 - Annual Report
2021-02-15 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________________ to _________________________________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its ch ...
Bio-Rad(BIO_B) - 2020 Q3 - Quarterly Report
2020-10-30 20:34
Financial Performance - Net sales for Q3 2020 were $647.3 million, a 15.5% increase from $560.6 million in Q3 2019, with a currency neutral increase of approximately 14.9%[152] - Sales for the first nine months of 2020 were $1.76 billion, a 4.1% increase from $1.69 billion in the same period of 2019, with a currency neutral increase of approximately 5.0%[164] Segment Performance - Life Science segment sales for Q3 2020 were $324.0 million, a 50.2% increase compared to the same period last year, driven by products supporting COVID-19 testing and research[153] - Clinical Diagnostics segment sales for Q3 2020 were $322.2 million, a decrease of 5.7% compared to Q3 2019, primarily due to lower demand from COVID-19[154] - Life Science segment sales for the first nine months of 2020 were $803.2 million, a 24.7% increase compared to the same period last year, with significant contributions from COVID-19 related products[165] - Clinical Diagnostics segment sales for the first nine months of 2020 were $945.6 million, a decrease of 8.5% compared to the same period last year, impacted by COVID-19[166] Profitability and Margins - Consolidated gross margins for Q3 2020 were 56.7%, up from 54.8% in Q3 2019, with Life Science segment gross margins increasing by approximately 5.3 percentage points[155] Expenses - Selling, general and administrative expenses decreased to $198.2 million or 30.6% of sales in Q3 2020, down from $201.6 million or 36.0% of sales in Q3 2019[156] - SG&A expenses decreased to $581.1 million or 33.1% of sales for the first nine months of 2020, down from $610.5 million or 36.2% of sales in the same period of 2019[169] - Research and development expenses increased to $59.5 million or 9.2% of sales in Q3 2020, compared to $47.9 million or 8.6% of sales in Q3 2019[157] - R&D expenses increased to $160.8 million or 9.2% of sales for the first nine months of 2020, compared to $145.6 million or 8.6% of sales for the same period in 2019[170] Cash Flow and Investments - Net cash provided by operations was $290.6 million for the first nine months of 2020, a decrease from $298.1 million in the same period of 2019[180] - Net cash used in investing activities was $10.1 million for the first nine months of 2020, significantly lower than $147.7 million for the same period in 2019[183] - Net cash used in financing activities was $101.2 million for the first nine months of 2020, compared to $18.0 million for the same period in 2019, primarily due to an $80 million increase in cash used to purchase treasury stock[184] Market Value and Equity - Change in fair market value of equity securities was a gain of $1.58 billion in Q3 2020, compared to a loss of $390.6 million in Q3 2019[161] - The change in fair market value of equity securities resulted in a gain of $3.59 billion for the first nine months of 2020, compared to a gain of $1.38 billion in the same period of 2019[173] Tax and Cash Position - The effective income tax rate was 22.5% for the nine months ended September 30, 2020, slightly down from 22.8% in the same period of 2019[175] - As of September 30, 2020, the company had $1.15 billion in cash, cash equivalents, and short-term investments, with approximately 25% held in foreign subsidiaries[177] - The company had no outstanding borrowings under its $200 million unsecured revolving credit facility as of September 30, 2020[177] Share Repurchase Program - The Board of Directors authorized an increase in the Share Repurchase Program by an additional $200 million, with $273.1 million remaining under the program as of September 30, 2020[189]
Bio-Rad(BIO_B) - 2020 Q2 - Quarterly Report
2020-07-31 20:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-1381833 ...
Bio-Rad(BIO_B) - 2020 Q1 - Quarterly Report
2020-05-08 01:55
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, I ...
Bio-Rad(BIO_B) - 2019 Q4 - Annual Report
2020-03-02 12:53
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________________ to _________________________________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its ch ...
Bio-Rad(BIO_B) - 2019 Q3 - Quarterly Report
2019-11-01 21:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIE ...
Bio-Rad(BIO_B) - 2019 Q2 - Quarterly Report
2019-08-06 18:03
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, IN ...
Bio-Rad(BIO_B) - 2019 Q1 - Quarterly Report
2019-05-10 20:08
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-1381833 ...
Bio-Rad(BIO_B) - 2018 Q4 - Annual Report
2019-03-30 01:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________________ to _________________________________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its ch ...